跳至主要内容
临床试验/NCT05474950
NCT05474950招募中1 期

Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2019年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
5
试验地点
1
主要终点
Change of cystoid macular edema

研究概览

简要总结

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant diagnosed with CME.
  • Participant aged from 18-60 years old.
  • Participant that signed the informed consent document and is able to complete the following visits.

排除标准

  • Participant is allergy to minocycline or tetracyclines.
  • Participant has no contraindications of minocycline or tetracyclines.
  • Participant has an abnormal function of liver, heart, kidney and thyroid.
  • Female that is pregnant, breast-feeding or planning to become pregnant.
  • Participant that is currently using other medications.

研究组 & 干预措施

minocycline

Experimental

干预措施: minocycline (Drug)

结局指标

主要结局

Change of cystoid macular edema

时间窗: At 6 months

Change of CME measured by Optical coherence tomography (OCT)

次要结局

  • Change of best corrected visual acuity (BCVA)(At 6 months)
  • Change of macular sensitivity(At 6 months)
  • Change of retinal vascular leakage(At 6 months)
  • Change of macular vessel(At 6 months)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dan Liang

Dan Liang, PhD

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验